Clinicopathologic characteristics and prognostic factors in patients with operable HER-2 overexpressing breast cancer

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 4, 2012, Pages 1197-1201

  Liu, Ai Na ^a   Sun, Ping ^a   Liu, Jian Nan ^a   Ma, Jin Bo ^a   Qu, Hua Jun ^a   Zhu, Hua ^a   Yu, Cai Yan ^a   Zhang, Liang Ming ^a  

^a QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

Author keywords

Breast cancer; Clinicopathology; HER2 overexpression; Multivariate analysis; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADJUVANT CHEMOTHERAPY; AGE; ARTICLE; BREAST TUMOR; CARCINOMA; DISEASE FREE SURVIVAL; FEMALE; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; METABOLISM; METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; TUMOR VOLUME;

AGE FACTORS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TUMOR BURDEN;

EID: 84873045231     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.4.1197     Document Type: Article

References (26)

1. Aaltomaa S, Lipponen P, Syrjanen K (1993). Proliferating cell nuclear antigen (PCNA) immunolabeling as a prognostic factor in axillary lymph node negative breast cancer. Anticancer Res, 13, 533-8.
2. Cianfrocca M, Goldstein LJ (2004). Prognostic and predictive factors in early-stage breast cancer. Oncologist, 9, 606-16.
3. Ellis MJ, Coop A, Singh B, et al (2001). Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol, 19, 3808-16.
4. Faneyte IF, Peterse JL, Van Tinteren H, et al (2004). Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement. Clin Cancer Res, 10, 4457-63.
5. Ferrero-Pous M, Hacene K, Bouchet C, et al (2000). Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis. Clin Cancer Res, 6, 4745-54.
6. Fisher B, Bauer M, Wickerham DL, et al (1983). Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer, 52, 1551-7.
7. Gianni L, Dafni U, Gelber RD, et al (2011). Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol, 12, 236-44.
8. Le Doussal V, Tubiana-Hulin M, Friedman S, et al (1989). Prognostic value of histologic grade nuclear components of Scarff-Bloom-Richardson (SBR). An improved score modification based on a multivariate analysis of 1262 invasive ductal breast carcinomas. Cancer, 64, 1914-21.
9. Menard S, Balsari A, Casalini P, et al (2002). HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors. Clin Cancer Res, 8, 520-5.
10. Moliterni A, Menard S, Valagussa P, et al (2003). HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer. J Clin Oncol, 21, 458-62.
11. Romond EH, Perez EA, Bryant J, et al (2005). Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med, 353, 1673-84.
12. Nemoto T, Natarajan N, Bedwani R, et al (1983). Breast cancer in the medial half. Results of 1978 National Survey of the American College of Surgeons. Cancer, 51, 1333-8.
13. Neville AM, Bettelheim R, Gelber RD, et al (1992). Factors predicting treatment responsiveness and prognosis in nodenegative breast cancer. The International (Ludwig) Breast Cancer Study Group. J Clin Oncol, 10, 696-705.
14. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al (2005). Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med, 353, 1659-72.
15. Polychemotherapy for early breast cancer: an overview of the randomised trials (1998). Early Breast Cancer Trialists' Collaborative Group. Lancet, 352, 930-42.
16. Revillion F, Bonneterre J, Peyrat JP (1998). ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer, 34, 791-808.
17. Rosen PP, Groshen S, Saigo PE, et al (1989). Pathological prognostic factors in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. J Clin Oncol, 7, 1239-51.
18. Ross JS, Fletcher JA (1998). The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy. Oncologist, 3, 237-52.
19. Slamon DJ, Eiermann W, Robert N, et al (2005). Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel(ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab(ACTH) with docetaxel, carboplatin and trastuzumab(TCH) in her2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res and Treat, 94, S5.
20. Sledge GW Jr, Miller KD (2003). Exploiting the hallmarks of cancer: the future conquest of breast cancer. Eur J Cancer, 39, 1668-75.
21. Tahan SR, Neuberg DS, Dieffenbach A, et al (1993). Prediction of early relapse and shortened survival in patients with breast cancer by proliferating cell nuclear antigen score. Cancer, 71, 3552-9.
22. Tamoxifen for early breast cancer: an overview of the randomised trials (1998). Early Breast Cancer Trialists' Collaborative Group. Lancet, 351, 1451-67.
23. Tang ZY (2000). Contemporary Oncology 2nd Ed. Shanghai Medical University Press, 2000.
24. Traina A, Agostara B, Marasa L, et al (2006). HER2/neu expression in relation to clinicopathologic features of breast cancer patients. Ann N Y Acad Sci, 1089, 159-67.
25. Xia W, Chen JS, Zhou X, et al (2004). Phosphorylation/ cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin Cancer Res, 10, 3815-24.
26. Yildirim E, Dalgic T, Berberoglu U (2000). Prognostic significance of young age in breast cancer. J Surg Oncol, 74, 267-72.